GH Research PLC
GHRS
Price:
$8.06
Market Cap:
$419.35M
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neur...[Read more]
Industry
Biotechnology
IPO Date
2021-06-25
Stock Exchange
NASDAQ
Ticker
GHRS
The ROE as of September 2024 (TTM) for GH Research PLC (GHRS) is -16.39%
According to GH Research PLC’s latest financial reports and current stock price. The company's current ROE is -16.39%. This represents a change of 296.73% compared to the average of -4.13% of the last 4 quarters.
GH Research PLC (GHRS) Historical ROE (quarterly & annually)
How has GHRS ROE performed in the past?
The mean historical ROE of GH Research PLC over the last ten years is -21.56%. The current -16.39% ROE has changed -23.97% with respect to the historical average. Over the past ten years (40 quarters), GHRS's ROE was at its highest in in the June 2022 quarter at 2.82%. The ROE was at its lowest in in the March 2021 quarter at -26.63%.
Average
-21.56%
Median
-7.87%
Minimum
-77.50%
Maximum
-2.86%
GH Research PLC (GHRS) ROE by Quarter and Year
Discovering the peaks and valleys of GH Research PLC ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 469.03%
Maximum Annual ROE = -2.86%
Minimum Annual Increase = -89.84%
Minimum Annual ROE = -77.50%
| Year | ROE | Change |
|---|---|---|
| 2023 | -16.25% | 469.03% |
| 2022 | -2.86% | -14.05% |
| 2021 | -3.32% | -57.78% |
| 2020 | -7.87% | -89.84% |
GH Research PLC (GHRS) Average ROE
How has GHRS ROE performed in the past?
The current ROE of GH Research PLC (GHRS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-7.48%
5-year avg
-21.56%
10-year avg
-21.56%
GH Research PLC (GHRS) ROE vs. Peers
How is GHRS’s ROE compared to its peers?
GH Research PLC’s ROE is greater than Molecular Partners AG (-33.08%), greater than MediciNova, Inc. (-13.37%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), less than Champions Oncology, Inc. (323.52%), greater than Cyteir Therapeutics, Inc. (-23.13%), greater than Mineralys Therapeutics, Inc. (-42.61%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than Janux Therapeutics, Inc. (-8.78%), greater than Rezolute, Inc. (-60.90%), greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than Pharvaris N.V. (-36.89%), greater than PepGen Inc. (-62.74%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Design Therapeutics, Inc. (-18.48%), greater than Werewolf Therapeutics, Inc. (-48.25%), greater than Ikena Oncology, Inc. (-42.81%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Arcus Biosciences, Inc. (-42.86%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Annexon, Inc. (-44.68%), greater than Structure Therapeutics Inc. (-20.15%), greater than Relay Therapeutics, Inc. (-43.66%),
| Company | ROE | Market cap |
|---|---|---|
| -33.08% | $172.94M | |
| -13.37% | $89.75M | |
| -122.97% | $54.20M | |
| 323.52% | $70.28M | |
| -23.13% | $108.71M | |
| -42.61% | $575.83M | |
| -47.03% | $549.22M | |
| -8.78% | $2.58B | |
| -60.90% | $285.64M | |
| -21.96% | $78.05M | |
| -36.89% | $1.14B | |
| -62.74% | $296.57M | |
| -70.40% | $359.95M | |
| -18.48% | $317.07M | |
| -48.25% | $93.52M | |
| -42.81% | $83.00M | |
| -57.89% | $769.71M | |
| -42.86% | $1.56B | |
| -28.37% | $975.75M | |
| -44.68% | $750.14M | |
| -20.15% | $2.31B | |
| -43.66% | $1.33B |
Build a custom stock screener for GH Research PLC (GHRS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GH Research PLC using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
GH Research PLC (GHRS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like GH Research PLC or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is GH Research PLC's ROE?
How is the ROE calculated for GH Research PLC (GHRS)?
What is the highest ROE for GH Research PLC (GHRS)?
What is the 3-year average ROE for GH Research PLC (GHRS)?
What is the 5-year average ROE for GH Research PLC (GHRS)?
How does the current ROE for GH Research PLC (GHRS) compare to its historical average?